Biomarkers to Diagnose Early Arthritis in Patients with Psoriasis

Gelfand J.M. , Gladman D.D. , Mease P.J. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005; 53: 573.

Ali Y. , Tom B.D. , Schentag C.T. , Farewell V.T. , Gladman D.D. Improved survival in psoriatic arthritis with calendar time. Arthritis Rheum. 2007; 56: 2708–14.

Moll J.M. , Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973; 3: 55–78.

Kane D. , Stafford L. , Bresnihan B. , FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience. Rheumatology (Oxford). 2003; 42: 1460–8.

Mease P.J. Psoriatic arthritis: Treatment update. Bull NYU Hosp Jt Dis. 2011; 69: 243–9.

Kingsley G.H. , Kowalczyk A. , Taylor H. A randomized placebo-controlled trial of MTX in PsA. Rheumatology (Oxford). doi: 10.1093/rheumatology/kes001 [E-pub ahead of print on February 17, 2012].

Gladman D.D. , Thavaneswaran A. , Chandran V. , Cook R.J. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011; 70: 2152–4.

Gladman D.D. , Shuckett R. , Russell M.L. , Thorne J.C. , Schachter R.K. Psoriatic arthritis (PSA): An analysis of 220 patients. Q J Med. 1987; 62: 127–41.

Anandarajah A.P. , Ritchlin C.T. The diagnosis and treatment of early psoriatic arthritis. Nat Rev Rheumatol. 2009; 5: 634–41.

O'Rielly D.D. , Rahman P. Genetics of susceptibility and treatment response in psoriatic arthritis. Nat Rev Rheumatol. 2011; 7: 718–32.

Ogdie A. , Gelfand J.M. Identification of risk factors for psoriatic arthritis: Scientific opportunity meets clinical need. Arch Dermatol. 2010; 146: 785–8.

Husted J.A. , Thavaneswaran A. , Chandran V. Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis. Arthritis Care Res (Hoboken). 2011; 63: 1729–35.

Jamnitski A. , Symmons D. , Peters M.J. , Sattar N. , McIinnes I. , Nurmohamed M.T. Cardiovascular comorbidities in patients with psoriatic arthritis: A systematic review. Ann Rheum Dis. doi: 10.1136/annrheumdis-2011-201194 [E-pub ahead of print on April 24, 2012].

Baeten D. , Demetter P. , Cuvelier C. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: Influence of disease duration and activity. Ann Rheum Dis. 2000; 59: 945–53.

Kruithof E. , Baeten D. , De Rycke L. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther. 2005; 7: R569–80.

Nestle F.O. , Kaplan D.H. , Barker J. Psoriasis. N Engl J Med. 2009; 361: 496–509.

Gottlieb A. , Menter A. , Mendelsohn A. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009; 373(9664): 633–40.

Ritchlin C. Psoriatic disease: From skin to bone. Nat Clin Pract Rheumatol. 2007; 3: 698–706.

Wagner E.F. , Schonthaler H.B. , Guinea-Viniegra J. , Tschachler E. Psoriasis: What we have learned from mouse models. Nat Rev Rheumatol. 2010; 6: 704–14.

Namey T.C. , Rosenthall L. Periarticular uptake of 99mtechnetium diphosphonate in psoriatics: Correlation with cutaneous activity. Arthritis Rheum. 1976; 19: 607–12.

Offidani A. , Cellini A. , Valeri G. , Giovagnoni A. Subclinical joint involvement in psoriasis: Magnetic resonance imaging and X-ray findings. Acta Derm Venereol. 1998; 78: 463–5.

Gisondi P. , Tinazzi I. , El-Dalati G. Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: A hospital-based case-control study. Ann Rheum Dis. 2008; 67: 26–30.

Gutierrez M. , Filippucci E. , De Angelis R. Subclinical entheseal involvement in patients with psoriasis: An ultrasound study. Semin Arthritis Rheum. 2011; 40: 407–12.

Naredo E. , Möller I. , de Miguel E. High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: A prospective case-control study. Rheumatology (Oxford), 2011; 50: 1838–48.

Gelfand J.M. , Wan J. , Callis Duffin K. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol. 2012; 148: 487–94.

Honigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol. 2001; 26: 343–50.

Menter A. , Korman N.J. , Elmets C.A. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010; 62: 114–35.

Johnson-Huang L.M. , Suárez-Fariñas M. , Sullivan-Whalen M. , Gilleaudeau P. , Krueger J.G. , Lowes M.A. Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol. 2010; 130: 2654–63.

Weichenthal M. , Schwarz T. Phototherapy: How does UV work? Photodermatol Photoimmunol Photomed. 2005; 21: 260–6.

Vahlquist C. , Larsson M. , Ernerudh J. , Berlin G. , Skogh T. , Vahlquist A. Treatment of psoriatic arthritis with extracorporeal photochemotherapy and conventional psoralen-ultraviolet A irradiation. Arthritis Rheum. 1996; 39: 1519–23.

Wilfert H. , Hönigsmann H. , Steiner G. , Smolen J. , Wolff K. Treatment of psoriatic arthritis by extracorporeal photochemotherapy. Br J Dermatol. 1990; 122: 225–32.

Mensah K.A. , Schwarz E.M. , Ritchlin C.T. Altered bone remodeling in psoriatic arthritis. Curr Rheumatol Rep. 2008; 10: 311–7.

Vignery A. Macrophage fusion: The making of osteoclasts and giant cells [comment]. J Exp Med. 2005; 202: 337–40.

Jones D. , Glimcher L.H. , Aliprantis A.O. Osteoimmunology at the nexus of arthritis, osteoporosis, cancer, and infection. J Clin Invest. 2011; 121: 2534–42.

Ritchlin C.T. , Haas-Smith S.A. , Li P. , Hicks D.G. , Schwarz E.M. Mechanisms of TNF-alpha– and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest. 2003; 111: 821–31.

Anandarajah A.P. , Schwarz E.M. , Totterman S. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis. 2008; 67: 296–301.

Ritchlin C. , Shao T. , Durham R. , Laudanski K. , Miller-Graziano C. , Schwarz E.M. Divergent pathways of monocyte effector cell differentiation in immune-mediated inflammatory disorders. Arthritis Rheum. 2005; 52: S391.

Ziegler-Heitbrock H.W. Heterogeneity of human blood monocytes: The CD14+ CD16+ subpopulation. Immunol Today. 1996; 17: 424–8.

Strauss-Ayali D. , Conrad S.M. , Mosser D.M. Monocyte subpopulations and their differentiation patterns during infection. J Leukoc Biol. 2007; 82: 244–52.

Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: Their role in infection and inflammation. J Leukoc Biol. 2007; 81: 584–92.

Fingerle G. , Pforte A. , Passlick B. , Blumenstein M. , Ströbel M. , Ziegler-Heitbrock H.W. The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients. Blood. 1993; 82: 3170–6.

Todd I. , Radford P.M. , Ziegler-Heitbrock L. , Ghaemmaghami A.M. , Powell R.J. , Tighe P.J. Elevated CD16 expression by monocytes from patients with tumor necrosis factor receptor–associated periodic syndrome. Arthritis Rheum. 2007; 56: 4182–8.

Takeyama N. , Yabuki T. , Kumagai T. , Takagi S. , Takamoto S. , Noguchi H. Selective expansion of the CD14(+)/CD16(bright) subpopulation of circulating monocytes in patients with hemophagocytic syndrome. Ann Hematol. 2007; 86: 787–92.

Nockher W.A. , Scherberich J.E. Expanded CD14+ CD16+ monocyte subpopulation in patients with acute and chronic infections undergoing hemodialysis. Infect Immun. 1998; 66: 2782–90.

Chiu Y.G. , Shao T. , Feng C. CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis. Arthritis Res Ther. 2010; 12: R14.

Kukita T. , Naohisa W. , Kukita A. RANKL-induced DC-STAMP is essential for osteoclastogenesis. J Exp Med. 2004; 200: 941–6.

Sawatani Y. , Miyamoto T. , Nagai S. The role of DC-STAMP in maintenance of immune tolerance through regulation of dendritic cell function. Int Immunol. 2008; 20: 1259–68.

Yagi M. , Miyamoto T. , Sawatani Y. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med. 2005; 202: 345–51.

Yagi M. , Miyamoto T. , Toyama Y. , Suda T. Role of DC-STAMP in cellular fusion of osteoclasts and macrophage giant cells. J Bone Miner Metab. 2006; 24: 355–8.

Iwasaki R. , Ninomiya K. , Miyamoto K. Cell fusion in osteoclasts plays a critical role in controlling bone mass and osteoblastic activity. Biochem Biophys Res Commun. 2008; 377: 899–904.

Chiu Y.H. , Mensah K.A. , Schwarz E.M. Regulation of human osteoclast development by dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res. doi: 10.1002/jbmr.531 [E-pub ahead of print on October 10, 2011].

Wilke C.M. , Bishop K. , Fox D. , Zou W. Deciphering the role of Th17 cells in human disease. Trends Immunol. 2011; 32: 603–11.

Kryczek I. , Bruce A.T. , Gudjonsson J.E. Induction of IL-17+ T cell trafficking and development by IFN-gamma: Mechanism and pathological relevance in psoriasis. J Immunol. 2008; 181: 4733–41.

Wilson N.J. , Boniface K. , Chan J.C. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007; 8: 950–7.

Lowes M.A. , Kikuchi T. , Fuentes-Duculan J. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008; 128: 1207–11.

Zaba L.C. , Cardinale I. , Gilleaudeau P. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007; 204: 3183–94.

Krueger G.G. , Langley R.G. , Leonardi C. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007; 356: 580–92.

Leipe J. , Grunke M. , Dechant C. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 2010; 62: 2876–85.

Chiu Y.G. , Schwarz E.M. , Wojciechowski W. Identification of a unique subset of DC-STAMP (dendritic cell-specific transmembrane protein) T cells with a Th17 signature in psoriatic arthritis (PsA) patients [abstract]. Arthritis Rheum. 2011; 63(suppl 10): 1704.

Toberer F. , Sykora J. , Göttel D. Tissue microarray analysis of RANKL in cutaneous lupus erythematosus and psoriasis. Exp Dermatol. 2011; 20: 600–2.

Dominguez P. , Husni M.E. , Garg A. , Qureshi A.A. Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire and the role of dermatologists: A report from the GRAPPA 2009 annual meeting. J Rheumatol. 2011; 38: 548–50.